Experienced in Apolipoprotein C2 Deficiency

John D. Baker

Middlemore, AUK, NZ 
Experienced in Apolipoprotein C2 Deficiency
Middlemore, AUK, NZ 
OverviewLocationsClinical Research

Overview

John Baker practices in Middlemore, New Zealand. Mr. Baker is rated as an Experienced expert by MediFind in the treatment of Apolipoprotein C2 Deficiency. His top areas of expertise are Type 2 Diabetes (T2D), Familial Hypertriglyceridemia, Familial Lipoprotein Lipase Deficiency, Apolipoprotein C2 Deficiency, and Laryngectomy.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Apolipoprotein C2 Deficiency.

Gender
Male

Locations

Middlemore, AUK, New Zealand
Other Locations
Manukau City, AUK, New Zealand
Counties Manukau Health
Otahuhu, AUK, New Zealand
Otara, STL, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 3
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above
A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Biological
Study Drugs: RSVPreF3 OA Investigational Vaccine, FLU-QIV
Study Phase: Phase 3
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Enrollment Status: Completed
Publish Date: September 21, 2021
Intervention Type: Drug
Study Drug: ARO-ANG3
Study Phase: Phase 1
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome
Enrollment Status: Completed
Publish Date: March 03, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

34 Total Publications

The Socio-Ecological Enablers of Smoking and Vaping in Rural Young Adults: A Mixed-Methods Study.
The Socio-Ecological Enablers of Smoking and Vaping in Rural Young Adults: A Mixed-Methods Study.
Journal: Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals
Published: October 18, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Baker's expertise for a condition
ConditionClose
        View All 9 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile